Kornimate/medical-research-clean huggingface dataset:
a pilot clinical trial investigating the effect of cutaneous cooling on sebum production

Conditions: Body Fat Disorder

Summary: to evaluate the safety and feasibility of reducing human sebum production using the zeltiq system.


Eligibility criteria:
inclusion criteria 1. male subjects \>18 years of age and \<25 years of age. 2. subject has an average sebum output on their upper back of at least 20, as measured by the sebumeter 3. subject has fitzpatrick skin phototypes i-iii (see appendix a) 4. willingness to participate in the study 5. willingness to receive experimental treatment 6. informed consent agreement signed by the subject 7. willingness to follow the treatment schedule and post treatment care requirements 8. willingness to not use topical or systemic retinoids or antibiotics during the course of the treatment exclusion criteria 1. subject has a history of isotretinoin use 2. subject has an infection or other dermatologic condition (aside from acne) in the area to be treated 3. subject has known cold sensitivity disorders including raynaud's phenomena, cold urticaria, cryoglobulinemia, and cold induced hemoglobinuria 4. presence of suntan in the area to be treated 5. subject is immunosuppressed 6. subject is unable to comply with treatment, home care or follow-up visits 7. subject has a history of vitiligo 8. subject has a history of keloid formation 9. subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 10. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Keywords: lipolysis cryolipolysis fat reduction
reported time between onset and diagnosis of alzheimer's disease: correlation with objective parameters

Conditions: Alzheimer Disease

Summary: the early diagnosis of alzheimer's disease is essential to enable patients to have access to the available treatments. however, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. in clinical practice, the hippocampal volume, measured by the scheltens index, is currently used as a marker of the progression of the disease. the purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the scheltens index.


Eligibility criteria:
inclusion criteria: alzheimer disease patients admitted in the 'memory clinic' of the chu brugmann hospital between 01-01-2010 and 31-01-2013. diagnose according to the dubois criteria exclusion criteria: none

Keywords: alzheimer disease objective parameters scheltens index
biweekly interval intermittent fasting for type 2 diabetes, a safety study

Conditions: Diabetes Type 2; Pre-diabetes

Summary: the purpose of this study is to establish safety of biweekly intermittent fasting in the setting of type 2 diabetes mellitus or prediabetes under treatment with non-hypoglycemic agents (e.g. metformin).

this study is proposed as a prospective interventional cohort safety study for biweekly intermittent fasting. in the effort to improve compliance of lifetime dietary change, the version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies. on fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories. furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day.

Eligibility criteria:
\*\*subjects must be able to get care at nellis air force base (a military installation) in order to participate in this study\*\* inclusion criteria: * male and female active duty members and dod beneficiaries ages 18-69 * diagnosed with type 2 diabetes or pre-diabetic * prescribed/taking metformin 500mg to 2000mg daily exclusion criteria: * history of recurrent hypoglycemic events on present medication regimen * drugs/medication with known increase in hypoglycemic events \[include basal insulin, rapid acting insulin, sulfonylureas, etc.). metformin is not known to cause hypoglycemia. * pregnant * medication-induced or secondary diabetes * known abnormal hematocrit
a multi-centre open study to assess the safety and efficacy of subgam®

Conditions: Primary Antibody Deficiency

Summary: the primary objective was to determine the efficacy of human normal immunoglobulin (subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. the secondary objective was to determine the safety of subgam® given subcutaneously by weekly infusion to patients with primary antibody deficiency.


Eligibility criteria:
inclusion criteria: * the main criteria for inclusion in the study were as follows: * a diagnosis of primary antibody deficiency; * no lower or upper age limit (any age was eligible); * with stable disease and receiving immunoglobulin (ivig or scig) therapy for at least six months prior to starting the study; * written informed consent (patient/parent/guardian). exclusion criteria: -
biomarkers of cytomegalovirus fetal infection and disease

Conditions: Cytomegalovirus Congenital

Summary: the purposes of this study are to determine 1) if the diagnosis of cmv fetal infection could be done directly in the maternal blood instead of requesting an amniocentesis and 2) if innovative technologies such as proteomic, transcriptomic, methylomic and lipidomic applied in fetal samples could allow the discovery of new biomarkers of fetal infection.

human cytomegalovirus (hcmv) is the most common cause of congenital infection worldwide. the diagnosis of cmv fetal infection relies on the detection of viral dna in amniotic fluid by polymerase chain reaction after amniocentesis. non-invasive diagnosis of fetal infection directly in maternal blood is not available. symptoms develop in about 10% of hcmv-infected fetuses. despite important advance in medical imaging, establishing the prognosis of an infected fetus remains challenging. thrombocytopenia, blood hcmv dna, anti-hcmv immunoglobulin m and β2-microglobulin are recognized biomarkers of symptomatic fetal infections. however, the predictive value of these individual markers is not. omics technologies could help to establish multimarker signatures of symptomatic infections. the objective of the study is to: * validate fetal blood hcmv dna, anti-hcmv immunoglobulin m , β2-microglobulin and platelet count as biomarkers of fetal disease; * identify new biomarkers of severe fetal disease using transcriptomic, methylomic and lipidomic analyses of fetal blood and of amniotic fluid. * validate a non-invasive cmv fetal infection diagnosis tool based on deep-sequencing of targeted cmv genes in maternal blood

Eligibility criteria:
inclusion criteria: cmv cases: * informed consent obtained from the mother; * pregnant women either with a history of primary cmv infection in pregnancy or carrying a fetus with ultrasound features compatible with cmv infection and willing to have amniocentesis for fetal diagnosis of cmv infection control cases : - pregnant women carrying a fetus with aneuploidy-dysgonosomy exclusion criteria: cmv cases: * fetuses older than the 26 weeks of gestation at the time of diagnosis of hcmv infection or impossibility to collect foetal samples by the end of the 26th week of gestation * mother unable to understand the protocol * absence of informed consent * any clinical rationale not to perform cordocentesis * mother \<18 years age * administration of immunoglobulins or anti-viral therapy to the mother before the collection of fetal samples or before the diagnosis of symptomatic fetal infection * administration of anti-hcmv drugs to the foetus before the collection of fetal samples or before the diagnosis of symptomatic fetal infection * administration of immunosuppressive drugs to the mother during pregnancy * maternal auto immune disorders * multiple pregnancies. control cases : * mother unable to understand the protocol * absence of informed consent

Keywords: cytomegalovirus congenital non-invasive diagnosis omics biomarkers
weight maintenance study for 2007 shape up ri participants

Conditions: Weight Loss

Summary: this study will focus on maintenance of weight loss achieved in the 2007 shape-up rhode island(suri)program. we plan to recruit 180 individuals who participated in suri and lost at least 10 pounds to take part in a 4-month weight loss maintenance program when the suri ends. participants will be randomly assigned to one of three groups: education, increased exercise, or daily self-weighing.


Eligibility criteria:
inclusion criteria: 1. are 18 years or older 2. lost 10 or more pounds during the 2007 shape up ri program 3. want to learn skills to maintain your weight loss 4. can come to the weight control and diabetes research center located at 196 richmond street in the "the jewelry district" of providence for a baseline assessment visit in mid-may/mid-june and final assessment visit in mid-october. 5. agree to be randomly assigned (which means you cannot choose) to one of the three weight loss maintenance interventions: general education, increased physical activity, or self-regulation 6. available to take part in six 30-minute conference calls on either a monday, tuesday or thursday starting at noon or 12:30pm. you will be given a toll-free call-in number so you can call from any location. the calls would be weekly for 4 weeks starting in june, and then there would be one call in mid-august and one in mid-september. exclusion criteria: 1. not 18 or more years old. 2. did not participate in the 2007 shape up ri program 3. participated in 2007 shape up ri but lost less than 10 pounds in the program. 4. currently or plan to become pregnant in the next 4 months. 5. currently participating in another weight loss or exercise study. 6. not available to take part in six 30-minute conference calls on either a monday, tuesday or thursday starting at noon or 12:30pm. the calls would be weekly for 4 weeks starting in june, and then there would be one call in mid-august and one in mid-september.
study to evaluate the efficacy and safety of a rilpivarine-based antiretroviral tratment regimen in hiv- infected patients with liver metabolic disease who maintain udetectable hiv viral load

Conditions: HIV Infections; Fatty Liver Disease

Summary: in hiv-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression and/or reduction of fatty metabolic liver disease, attenuating inflammation and liver fibrosis.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age with hiv infection who have never received antiretroviral treatment with rilpivirine. * have a stable art pattern for at least the last 6 month exclusion criteria: * not having received more than three previous lines of antiretroviral treatment * no resistance mutations that compromise the efficacy of rilpivirine, dolutegravir, tenofovir (tdf and/or taf) or emtricitabine. * have an hiv viral load \< 50 copies/ml for at least the last 6 months, 1 blip below 500 copies/ml is allowed during this period. * have an ultrasound-diagnosed fatty liver metabolic disease or a cap (controlled attenuation parameter®) measurement \> 238 db/m with an iqr \< 30 db/m. * have an fatty liver metabolic disease with some degree of fibrosis diagnosed by et (fibroscan®) \> 5.2 kpa. in patients in whom et is not possible, have a fib-4 \>1.3. * be able to understand and comply with the requirements and instructions of the protocol. * understanding long-term commitment to study * acceptance of their participation in the study by signing an informed consent form. exclusion criteria: * have chronic hbv infection (presence of hbsag+) or hcv (detectable hcv viral load). patients with past treated hcv are also not allowed to be included (does not include patients with spontaneously resolved hcv infection). * have diabetes mellitus on treatment with sglt2, glp1 or plioglitazone of less than 6 months duration. * have a history of alcohol abuse * harmful alcohol consumption, defined as \>30 grams of alcohol per day in men and \>20 grams of alcohol per day in women. * have chronic decompensated liver disease, defined as any of the following: presence of encephalopathy, ascites, coagulopathy, oesophageal or gastric varices, or persistent jaundice. * any previous physical or mental condition (such as habitual drug use) that the investigator believes may interfere with the patient's ability to comply with the study protocol. * pregnancy or breastfeeding at the screening visit or at any time during the study or intention to become pregnant during the study period. * prior history of rilpivirine use of any duration.
trauma-focused cognitive behavior therapy for youth: effectiveness in a community setting

Conditions: Posttraumatic Stress Disorder

Summary: this effectiveness study is being conducted to determine whether trauma-focused cognitive therapy (tf-cbt), a treatment model developed in specialty clinics by experts in the treatment of child sexual abuse, can be effectively transported to a state-contracted community mental health agency in the state of delaware and used effectively by clinicians with little prior tf-cbt experience. the sample is comprised of youths receiving public mental health services and with diverse trauma histories.

this investigation aims to examine the effectiveness of trauma-focused cognitive behavioral therapy (tf-cbt) in treating child traumatic stress when implemented in community settings on a state-wide level in delaware. youth (ages 7-16 years) with a history of documented trauma (sexual or physical abuse, traumatic loss, domestic or community violence) and symptoms of posttraumatic stress disorder (ptsd) receive approximately 10 sessions of tf-cbt delivered in a state-contracted mental health agency. children and adolescents are recruited from a public mental health population. ptsd symptoms and internalizing and externalizing behavior problems have been assessed in the first 72 participants at pre-treatment and then at 3-, 6-, 9-, and 12-months after intake; subsequent participants (n=38) are only being assessed for symptoms and problems at pre-treatment and then at 3-, 6-months after intake.

Eligibility criteria:
inclusion criteria: * child is 7-17 years old * positive screen for ptsd * child qualifies for public insurance * parent willing to co-participate in treatment * english-speaking (child and parent) exclusion criteria: * intellectual disability (child) * untreated psychosis (child) * untreated substance abuse (child) * sibling already in study * unable to participate in year-long follow-up (e.g., moving out of state)

Keywords: posttraumatic stress disorder trauma-focused cognitive behavioral therapy trauma child abuse
multicenter clinical study to examine the efficacy and safety of zarzenda in patients with hand eczema

Conditions: Hand Eczema

Summary: to show efficacy of zarzenda in the treatment of hand eczema

the objective of the study is to demonstrate efficacy and safety of zarzenda (a medical device) in the management of hand eczema.

Eligibility criteria:
inclusion criteria: * mild to moderate hand eczema for at least 3 months * at least 4 weeks have passed since use of systemic treatment for eczema * at least 4 weeks have passed since any vaccination * at least 1 week has passed since last topic treatment on hands with corticosteroids * agree to use adequate contraceptive method if of childbearing potential * willingness to avoid excessive exposure to sunlight and avoid skin irritants exclusion criteria: * pregnancy, breast feeding * severe excoriations on the hands * need for systemic treatment for atopic dermatitis * known sensitivity to zarzenda and/or to extract of nut butyrospermum parkii (shea) * known immune deficiency * concomitant infection on hands

Keywords: eczema medical device
improving access to services to community based outpatient clinics (cboc's)

Conditions: Panic Disorder

Summary: the purpose of this study is to examine the feasibility of delivering ipct in three rural va community based outpatient clinics (cbocs).

we will first need to develop a more thorough understanding of the potential barriers associated with implementing this novel form of treatment in these settings by conducting focus groups at each facility. this information will then be used to modify the treatment, which will then be piloted with veterans enrolled in these clinics who have panic disorder.

Eligibility criteria:
inclusion criteria: * oef/oif/ond veteran with current diagnosis of panic disorder with or without agoraphobia (presence of other anxiety disorders is acceptable) exclusion criteria: * current substance dependence * psychosis * symptomatic bipolar disorder * severe depression with suicidal intent or plan

Keywords: panic anxiety
the kampala trauma score in the outcome of polytrauma patients

Conditions: Polytrauma Patients

Summary: the goal of this observational study is to learn about the predictive value of the kampala trauma score in egypt. the main question it aims to answer is: how does the performance of the kampala trauma score compare to the estimated injury severity score in predicting outcomes for multi-traumatic patients in egypt? participants are adult polytrauma patients admitted to the emergency department during the study period.

two prominent scoring systems used in trauma care are the kampala trauma score (kts) and the estimated injury severity score (eiss). the kts was specifically designed for use in low-resource settings, offering a practical tool for predicting patient outcomes based on readily available clinical data. this score integrates parameters such as age, systolic blood pressure, and glasgow coma scale (gcs) scores, making it suitable for environments where advanced diagnostic tools may be lacking. previous research has demonstrated the kts's utility in various resource-limited settings, highlighting its role in effectively stratifying trauma patients and guiding triage decisions. in contrast, the estimated injury severity score (eiss) is an adaptation of the injury severity score (iss), which incorporates both clinical and radiographic data to assess trauma severity comprehensively. the eiss uses an estimated approach to account for the often incomplete or preliminary information available in some clinical settings, aiming to provide a robust prediction of patient outcomes. while it is a more comprehensive tool than the kts, its reliance on advanced imaging and detailed clinical information may limit its applicability in settings with restricted resources. this study aims to conduct a cross-sectional comparison of the kts and eiss to evaluate their relative effectiveness in assessing trauma severity and predicting patient outcomes. the results will provide valuable insights into the optimal use of trauma scoring systems and potentially inform improvements in trauma care practices

Eligibility criteria:
inclusion criteria: * adult polytrauma patients * both genders exclusion criteria: * patients with incomplete data or those who decline participation. * patients with multiple comorbidities. * patients managed outside the hospital.
burn wound management of betafoam® and allevyn® ag

Conditions: Acute Burn

Summary: this is a randomized, controlled, multi-centre, open-label study. a total of 40 patients will be enrolled in this study. patients will be randomly assigned to betafoam® or allevyn® silver dressing for burn wounds after acute burn injury.


Eligibility criteria:
inclusion criteria: 1. adults ≥ 19 years 2. subjects of second-degree burn who have acute partial thickness burn (superficial to deep partial thickness) via investigator's visible assessment 3. burn total body surface area of \<15% range based on lund and browder chart presenting at the emergency room within the first 3\~5 days post-injury will be considered for inclusion in this study. (if more than one burn wound is present that meets the inclusion criteria, the largest one among wounds that size are between 10x10 ㎝ and 20x20㎝ will be preferred to select as the target wound.) 4. subjects who voluntarily sign the informed consent form exclusion criteria: 1. pregnant \& lactating females 2. known allergy to the dressing product including pvp-i 3. known hyperthyroidism or other acute thyroid diseases 4. subject with clinical infection who should be administered antibiotics continuously after enrolment 5. subject has any condition(s) that seriously compromises the patient's ability to complete this study. 6. subject has participated in interventional study utilizing an investigational drug within the previous 30 days 7. subject has one or more medical condition(s), diabetes, including renal, hepatic, hematologic, neurologic, or immune disease that presumably to hinder the wound healing processes by the physician's judgement. 8. subjects who are immune suppressed states, under chemo- or radiotherapy. 9. the surgeon decides that surgery is necessary or requiring skin grafting. 10. burn injury sites at the ends of extremities and genitalia 11. burn injury caused of electronic burn 12. subjects who have inhaled damage, severe head injury or fracture on burn wound 13. scintillation scan for the diagnosis of thyroid takes at intervals of 1 to 2 weeks when using this dressing 14. vulnerable subjects.

Keywords: dressing for burn wounds